Achalasia cardia is one of the common causes of motor dysphagia. Though the disease was first described more than 300 years ago, exact pathogenesis of this condition still remains enigmatic. Pathophysiologically, achalasia cardia is caused by loss of inhibitory ganglion in the myenteric plexus of the esophagus. In the initial stage, degeneration of inhibitory nerves in the esophagus results in unopposed action of excitatory neurotransmitters such as acetylcholine, resulting in high amplitude non-peristaltic contractions (vigorous achalasia); progressive loss of cholinergic neurons over time results in dilation and low amplitude simultaneous contractions in the esophageal body (classic achalasia). Since the initial description, several studies have attempted to explore initiating agents that may cause the disease, such as viral infection, other environmental factors, autoimmunity, and genetic factors. Though Chagas disease, which mimics achalasia, is caused by an infective agent, available evidence suggests that infection may not be an independent cause of primary achalasia. A genetic basis for achalasia is supported by reports showing occurrence of disease in monozygotic twins, siblings and other first-degree relatives and occurrence in association with other genetic diseases such as Down's syndrome and Parkinson's disease. Polymorphisms in genes encoding for nitric oxide synthase, receptors for vasoactive intestinal peptide, interleukin 23 and the ALADI� gene have been reported. However, studies on larger numbers of patients and controls from different ethnic groups are needed before definite conclusions can be obtained. Currently, the disease is believed to be multi-factorial, with autoimmune mechanisms triggered by infection in a genetically predisposed individual leading to degeneration of inhibitory ganglia in the wall of the esophagus.
INTRODUCTION
Achalasia is an esophageal motor disorder characterized by aperistalsis of the esophageal body and lack of relax� ation of the lower sphincter in response to swallows. It affects both sexes and all age groups [1, 2] . Achalasia was first described by Willis [3] in 1674 as "food blockage in esophagus". He treated these patients successfully with a dilator made of whale bone and sponge [3] . The term "achalasia" was first coined by Hurst [4] in 1927. He had observed such patients since 1914 and suggested that their disorder might be due to absence of normal relax� ation of the sphincter, possibly resulting from organic changes in Auerbach's plexus [5] . Achalasia is a Greek word that means "failure of relaxation". Achalasia can be primary (idiopathic) or secondary. In secondary achalasia, the cause for the degeneration of esophageal nerve fibers is known. Pathophysiologically, achalasia is caused by loss of inhibitory ganglion cells in the myenteric plexus. Since the initial description, several studies have attempted to explore initiating agents that may cause the disease such as viral infection, other environmental factors, autoimmu� nity, and genetic factors. However, the exact pathogenesis of primary achalasia is still not known. In this paper, the literature regarding pathogenesis of primary achalasia is reviewed.
PATHOPHYSIOLOGICAL ISSUES
The pathophysiology of achalasia is outlined in a simpli� he pathophysiology of achalasia is outlined in a simpli� is outlined in a simpli� in a simpli� fied manner in �igure ��� �n healthy esophagus�� progres� in �igure ��� �n healthy esophagus�� progres� �igure ��� �n healthy esophagus�� progres� ure 1. In healthy esophagus, progres� 1. In healthy esophagus, progres� sive delay in contractility of the lower esophageal muscles results from the presence of inhibitory neurotransmit� ters such as nitric oxide and its receptors in the lower esophagus (�igure �� ure 1) 1) [6, 7] . In the initial stage of the disease, degeneration of inhibitory nerve fibers in the esophagus results in unopposed action of excitatory neurotransmit� ter such as acetylcholine, which leads to high amplitude non�peristaltic contractions (not progressively delayed or simultaneous) [8] . This stage of achalasia is known as vigorous achalasia (average amplitude of contractions in lower esophagus > 40 mmHg) ) [9] . Progressive loss of cholinergic neurons results in dilation and low amplitude simultaneous contractions in the esophageal body; this stage of achalasia is called classic achalasia. Studies dem� onstrating reduction in number of ganglion cells in the esophageal body at autopsy of patients with achalasia and an inverse correlation between number of ganglion cells and duration of disease support their involvement in the disease process [8] . In experimental studies published long ago, a muscles strip obtained from the esophageal body of patients with esophageal achalasia failed to contract on addition of the ganglion stimulant nicotine though it contracted in response to acetylcholine, which is a direct muscle stimulant. A muscle strip from the lower esopha� geal sphincter (LES) of patients with achalasia contracted in response to acetylcholine though it failed to relax in response to nicotine [10] �� These findings demonstrate that in patients with achalasia, there is degeneration of gan� glia though the muscles remain contractile in response to acetylcholine. Degeneration of inhibitory control of the LES has also been demonstrated by studies that showed cholecystokinin, which reduces LES pressure in healthy subjects, increases pressure in patients with acha� lasia [8] ; esophageal distension failed to cause relaxation of LES in these patients [11] and gastric distension failed to induce transient LES relaxation [12] . All the above data suggest that achalasia results from degeneration of the esophageal nerve plexus�� particularly the inhibitory fibers�� However�� neural degeneration might not be confined to the esophagus alone as evidenced by demonstration of Wallerian degeneration in the vagus nerve on electron microscopy [13] , improvement in some abnormalities with stimulation of vagus nerve in animal models [14, 15] , pres� ence of Lewy bodies in the brainstem of patients with achalasia [16] , and delayed gastric emptying [17] and abnormal gastric secretory response to insulin�induced hypogly� cemia in a subset of patients [18] . It is, however, not clear why some people develop neural degeneration causing achalasia. The various environmental, autoimmune and genetic factors incriminated in pathogenesis are reviewed below.
A study in an animal model showed that the nitric oxide inhibitor, recombinant human hemoglobin, caused incomplete LES relaxation and high amplitude simultane� ous contractions in the body of the esophagus [19] . Similar results have been reported in humans [20] . Another study in an animal model failed to show an association of intra� muscular interstitial cells of Cajal in the nitrenergic path� way and dysfunction of LES found in achalasia [21] .
Infection
A number of studies implicating viral agents in the pa� thogenesis of achalasia showed conflicting results. An initial report by Jones et al [22] showed a statistically signifi� cant increase in antibody titer against measles virus (MV) in patients with achalasia compared with controls (14 of 21 achalasia patients vs 7 of 21 controls, P <� 0.05).
0.05). 0.05). This difference persisted only at a titer of 1/32 or more. How� ever, there was similar frequency of infection in both groups as was evident by similar antibody detection rates at low titer [22] . Robertson et al [23] reported an association between Varicella zoster virus (VZV) infection in patients with achalasia by demonstrating viral DNA in esophageal tis� sue. They demonstrated VZV particles by DNA hybrid� ization techniques in three of nine esophageal myotomy specimens from achalasia patients, but in none from 20 control subjects. DNA probes for cytomegalovirus (CMV) and herpes simplex virus type 1 (HSV�1) were negative in both achalasia patients and controls [23] . This study provided an attractive hypothesis, but failed to es� tablish a causal association. We have reported one patient who presented with motor dysphagia due to esophageal hypomotility and also developed gastroparesis following infection with VZV [24] . A few studies, however, failed to show evidence of in� fection as a cause for achalasia [25, 26] . Niwamoto et al [25] used polymerase chain reaction to detect human herpes virus DNA (HSV�1 and 2, CMV, VZV, Epstein�Barr virus and human herpes virus�6) or MV RNA in the esophageal muscle of 12 patients with achalasia and six with upper esophageal carcinoma. Only HSV�1 and 2 were detected in all samples including patients and controls. Other vi� ruses were not detected. Similarly, another study failed to detect human herpes virus, MV and human papilloma virus sequences both in achalasia or control specimens [26] . Two studies proposed an association between MV and VZV infection in patients with achalasia [22, 23] . However, VZV particles were found only in a third of achalasia patients [23] . Moreover, not all patients with VZV and MV infection develop achalasia. It has been hypothesized that most patients might have cleared virus or there could be sampling error. However, most of these data suggest that VZV may not be an important cause of achalasia.
Considering the above possibilities, a recent study tried to demonstrate infection in the absence of direct evidence of virus in esophageal tissue�� �acco et al [27] reported oligoclonal selection of T cells in achalasia patients by flow cytometry and CDR3 length spectra typing analysis of lymphocytes. They also demonstrated increased proliferation of T cells and Th�1 type cytokine release in response to HSV�1 antigen. In conclusion, available evidence suggests that infection may not be a definite cause for esophageal achalasia�� One strong piece of evidence in favor of infection in the pathogenesis of achalasia, however, is the fact that Chagas disease, caused by Trypanosoma cruzi, very closely mimics the pathophysi� ology of primary achalasia [28] .
Immunological factors
An autoimmune etiology for achalasia has been consid� ered because of the presence of neural inflammation in absence of conclusive evidence of infection. Studies have demonstrated inflammatory cell infiltrate of the myen� teric plexus in 90%�100% of esophageal specimens from achalasia patients [29, 30] . This hypothesis has been further supported by the presence of autoantibody in sera of patients with achalasia (Table 1 ) and an association with major histocompatibility complex class Ⅱ antigen (Table  2��� �mmune activation and inflammation is known to be associated with altered gastrointestinal motility due to neu� ral dysfunction in the gut [31] . Taking the analogy of other gastrointestinal motility disorders such as post�infectious irritable bowel syndrome, intestinal pseudo�obstruction and ileus, it has been postulated that achalasia may have a similar pathophysiological basis [31] . However, more studies are needed on this issue.
Autoantibodies in achalasia����
Several studies showed a higher prevalence of autoantibodies in achalasia patients compared to controls. Storch et al [32] 2] ] suggested a role of autoimmunity by demonstrating a higher prevalence of anti�myenteric autoantibody in achalasia patients (64%) Achalasia cardia compared to healthy controls (7%). They also showed absence of anti�myenteric autoantibody in Hirschsprung' s disease as well as in esophageal cancer patients, and in 8%�9% of patients with peptic esophagitis and myasthe� nia gravis [32] 2] ] . This hypothesis was further supported by subsequent studies [33, 34] . Another interesting study demonstrated that patients with Chagasic achalasia more often had autoantibodies against muscarinic acetylcholine receptors [M(2) mAchR] as compared to patients with achalasia not resulting from Chagas disease [35] 
. Verne et al [33] 3] ] tried to demonstrate the presence of re� gional and cellular specific antibody in achalasia patients�� Staining of the esophageal and intestinal sections of rat with sera from achalasia patients showed binding of an� tibody to neurons in the esophageal as well as intestinal sections, though none of the sera of patients with gas� troesophageal reflux disease (GERD� or controls showed staining [33] 3] ]
. Since idiopathic achalasia is primarily a disor� der of esophageal smooth muscles, binding on intestinal sections may suggest non�specific binding of this anti� body and hence, may not suggest a causal association.
A study by Moses et al [36] 6] demonstrated a similar de� gree of immune�reactivity in the myenteric plexus of the esophagus and ileum of guinea�pig and mouse when im� mune�stained with sera of achalasia and GERD patients; GERD patients; GERD patients; however, both the groups had higher immune�reactivity when compared with normal individuals. Western blot� ting analysis failed to reveal specific myenteric neuronal proteins that could be targeted by antibodies in achalasia or GERD serum [35] . These observations do not support anti�neuronal antibodies to be causative in achalasia. These antibodies may perhaps be an epiphenomenon.
Human leukocyte antigen association���� An association between achalasia and human leukocyte antigen (HLA)
human leukocyte antigen (HLA) uman leukocyte antigen (HLA) (HLA) HLA) ) class Ⅱ histocompatibility antigens was proposed for the first time by Wong et al [37] 7] ]
. They performed HLA typing on 40 achalasia patients and found that Caucasians and black populations with DQw1 had 4.2 and 3.6 times high� er risk of developing achalasia, respectively [37] 
. Subsequent Subsequent Subsequent studies [38, 39] . Another study showed higher frequency of DQA1*0103, DQB1*0603 and DQA1*0103�DQB1*0603 heterodimer in patients with achalasia compared to con� trols. They also demonstrated that achalasia patients with DQA1*0103 and DQB1*0603 alleles had significantly higher prevalence of anti�myenteric antibody [34] 4] ]
. In con� trast, Latiano et al [40] 40] ] failed to show any correlation among HLA alleles and anti�neuronal antibodies. However, acha� However, acha� lasia patients had higher frequency of DQB1*0502 and DQB1*0601 alleles. All these reports might suggest an autoimmune etiology of achalasia; however, not all pa� tients with achalasia had predisposing HLA while not all people with the specific HLA had the disease�� �n conclusion�� all these data are not sufficient to con� 
Achalasia Control
Storch et al [32] Indirect immunofluorescence 37/58 (64) 4/54 (7) in healthy < 0.0001 Absent in 12 of Hirschsprung's disease Absent in 12 esophageal cancer Verne et al [33] Double-label Indirect immunofluorescence 7/18 (40) Absent in 22 healthy < 0.05 Absent in 9 GERD Ruiz-de-León et al [34] Indirect immunofluorescence 50/92 (54.3) 3/40 (7.5) < 0.001 Moses et al [36] Immunohistochemistry 23/45 (51) 2/22 (9) in healthy control < 0.001 8/16 (50) of GERD NS GERD: Gastroesophageal reflux disease; NS: Not significant. clude that achalasia is an autoimmune disease�� To define a disease as autoimmune in nature, the disease should provide the following three features: (1) . To date, all the evidence to support an autoimmune etiology of achalasia has not been substantiated. More studies are needed on this issue.
Genetic factors���� Some evidence supports a genetic basis for achalasia. The disease has been reported in monozy� gotic twins [42] . Studies showed genetic correlations of the ALADIN gene in achalasia associated with Allgrove syndrome [47, 48] . Additionally, the disease has also been reported in association with other genetic diseases such as Down's syndrome and Parkinson disease [49, 50] . The genetic basis for achalasia might have been underestimated, in contrast to that for Hirschsprung's disease, though both these enteric neuropathies have sev� eral features in common [51] . Hirschsprung's disease, like achalasia, is also known to have familial occurrence and the former has been reported quite commonly in differ� ent syndromes with a genetic basis. Both the conditions have altered motor function with loss of inhibitory in� nervation [51] . We wish to review some studies on genetic polymorphisms in certain genes in patients with achalasia cardia.
Nitric oxide synthase polymorphism���� Nitric oxide is a necessary inhibitory neurotransmitter of the esopha� geal myenteric plexus involved in esophageal sphincter relaxation. Nitric oxide synthase (NOS) synthesizes ni� tric oxide from L�arginin. Reported studies showed that in patients with achalasic cardia, the LES has less NOS compared with controls [52, 53] . At present, three differ� ent NOS isozymes, neuronal NOS (NOS1), inducible NOS (NOS2) and endothelial NOS (NOS3) have been reported. NOS1, NOS2 and NOS3 genes are located on human chromosomes 12q24.2, 17q11.2�q12 and 7q36, respectively. A microsatellite (CA repeat) polymorphism is found within the 3'�untranslated region of exon 29 of the NOS1 gene. The NOS2 gene has two biallelic poly� morphisms in exons 16 and 22 representing C/T and G/ A transitions, respectively, and NOS3 shows a 27�bp vari� able number of tandem repeat polymorphisms in intron 4. Published studies have failed to explain a strong role for these functional polymorphisms in the susceptibility for achalasia [54, 55] . VIPR1 is present on myenteric neurons of the distal esophagus and LES; continued inflammation leads to the impairment of VIPR1 signaling, which alters the effect of VIP on myenteric neurons that progresses to ganglion cell loss and nerve fiber fibrosis . Paladini et al al al [64, 65] reported five single nucleotide polymorphisms in the VIPR1 gene in patients with achalasia cardia which included (rs421558) Intron�1, (rs437876) Intron�4, (rs417387) Intron�6, rs896 and rs9677 (3'UTR) and they found that the presence of A allele at (rs421558) Intron�1 and C allele at rs896 (3' UTR� was associated with a less efficient down�regulation of the receptor. Hence, AC haplotype may protect from the disease by down�regulation of VIPR1 receptor during inflammation�� Interleukin-23 receptor polymorphism���� The interleu� kin�23 receptor (IL-23R) gene, located on chromosome Ip31, encodes for heterodimeric subunits of the IL�23R p31, encodes for heterodimeric subunits of the IL�23R complex [66] 6] ] . IL�23R is a type Ⅰ trans�membrane protein expressed on Th1 derived T�cells which produce IL�17, designated as Th17 cells. Previous data support a role for Th�7 cells and these cytokines in inflammatory and autoimmune processes [67] 7] ]
. Activated JAK�STAT signaling pathway by IL�23 binds with the IL�23R/IL�12β1 recep� tor, which influences the number of downstream im� mune responses [66] 
. Reported studies showed that IL�23R is associated with inflammatory as well as chronic autoim� mune disorders
. In a single nucleotide polymorphism of the IL-23R gene, arginine replaces glutamine at codon 381. One study reported IL-23R coding variant 381Gln was a protective allele, whereas another study found this variant to be a risk factor. de León et al al al [75] 5] ] reported coding variant 381Gln of IL-23R was significantly more com� mon in patients with achalasia as compared with healthy controls. Hence, this 381Gln variant of IL-23R polymor� phism could be a risk factor for achalasia cardia.
Protein tyrosine phosphatase non-receptor 22 gene polymorphism���� The protein tyrosine phosphatase non� receptor 22 (PTPN22) gene is located on chromosome 1p13.3�p13, a region associated with autoimmune dis� ease [75, 76] . The PTPN22 gene exhibits a single nucleo� tide polymorphism at position 1858C/T, which leads to a replacement in codon 620 of Arg (R) to Trp (W). A study showed that Lyp�W620 had more phosphatase activity, which could slow down T�cell signaling more effectively than Lyp�R620. In a different population it has already been reported that the PTPN22 T allele is a risk factor for autoimmune diseases [ [84] 4] ] reported that PTPN22 C1858T polymorphism increased risk of achalasia in a Spanish population.
CONCLUSION
Achalasia is caused by loss of inhibitory ganglion in the myenteric plexus in the esophagus. Gradual progression of neuronal degeneration is associated with progression of the disease from vigorous to classic achalasia. Though several studies have attempted to explore initiating agents that may cause the disease, the exact factors responsible for the degeneration of ganglion cells in the myenteric plexus are poorly understood. The disease is likely to be multi�factorial involving host genetic factors, autoimmu� nity, and environmental factors such as infections. More studies are needed to explore the exact cause of this enig� matic disease.
